Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Patients across New Jersey — from Absecon to smaller communities — are transforming their lives with FDA-approved GLP-1 medications through licensed telehealth. For many, it is the breakthrough they have been waiting for after years of struggling with traditional approaches. Our NJ-licensed physicians evaluate your eligibility and build a personalized GLP-1 treatment plan designed for maximum results.
GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound are prescribed by state-licensed physicians applying the same clinical guidelines used at academic obesity medicine centers. Randomized trial data demonstrates 15–22% mean body weight reduction across treatment periods of 56–72 weeks.
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 5, 2026
New Jersey supports patients seeking transformative weight management through licensed telehealth. All providers hold active NJ medical licenses and follow evidence-based treatment protocols for GLP-1 prescribing — ensuring your transformation is built on a solid medical foundation.
Select your New Jersey city to begin your health transformation. Licensed GLP-1 specialists are serving patients in every corner of the state.
GLP-1 receptor agonists are among the most rigorously studied obesity treatments, with evidence from placebo-controlled trials published in the New England Journal of Medicine:
New Jersey authorizes board-certified licensed physicians to prescribe FDA-approved GLP-1 medications via telehealth after a valid patient-physician relationship is established through an online consultation. GLP-1 receptor agonists are not DEA-scheduled controlled substances — no in-person visit is legally required in New Jersey.
Life-changing GLP-1 results extend beyond New Jersey — our transformation network covers all neighboring states and all 50 states nationwide.
Licensed telehealth GLP-1 care is available statewide. Select a city to begin your clinical assessment with a state-licensed, board-certified physician.
Local weight loss and GLP-1 providers serving the New Jersey area, based on Google Business listings.
2186 NJ-27 Suite 1B, North Brunswick Township, NJ 08902
(732) 659-6650
4.5/5 ★ (121 reviews)
Visit website →Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
New Jersey patients using semaglutide (Wegovy) achieve an average of 15% body weight loss over 68 weeks. Those on tirzepatide (Zepbound) see up to 22% average weight reduction over 72 weeks. Beyond the scale, patients report dramatic improvements in energy, blood pressure, blood sugar, and overall quality of life.
Most New Jersey patients notice reduced appetite within the first 1-2 weeks. Visible weight loss typically begins within the first month and accelerates with dose titration. The most significant transformation typically occurs between months 3-6, with continued improvement throughout treatment.
Yes. GLP-1 medications work through hormonal mechanisms that address the biological roots of excess weight — not just behavior. Many New Jersey patients who struggled for years with conventional approaches achieve breakthrough transformation with GLP-1 because it directly addresses appetite regulation and metabolic dysfunction.
GLP-1 transformation goes beyond weight loss. New Jersey patients experience measurable improvements in HbA1c, systolic blood pressure, triglycerides, LDL cholesterol, joint pain, sleep quality, and cardiovascular risk. The SELECT trial showed semaglutide reduced major cardiac events by 20% in at-risk patients.
Clinical evidence shows weight is often maintained during treatment. To sustain transformation after discontinuation, physicians recommend pairing GLP-1 therapy with lifestyle changes. New Jersey physicians offer ongoing support and maintenance dosing options to help patients preserve their results long-term.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
